title: Efficacy of duloxetine add on in treatment of inflammatory bowel disease patients: A double-blind controlled study.
abstract: BACKGROUND
  Treating inflammatory bowel disease (IBD) with antidepressants might be of utility to improve patient's condition. The aim of this study was to assess the efficacy of Duloxetine on depression, anxiety, severity of symptoms, and quality of life (QOL) in IBD patients.
  
  
  METHODS
  In a randomized, double-blind, controlled clinical trial on 2013-2014, in Alzahra Hospital (Isfahan, Iran), 44 IBD patients were chosen to receive either duloxetine (60 mg/day) or placebo. They were treated in a 12 weeks program, and all of the participants also received mesalazine, 2-4 g daily. We assessed anxiety and depression with Hospital Anxiety and Depression Scale, the severity of symptoms with Lichtiger Colitis Activity Index and QOL with World Health Organization Quality of Life Instruments, before and just after the treatment. The data were analyzed using Paired sample t-test and ANCOVA.
  
  
  RESULTS
  In 35 subjects who completed the study, the mean (standard error [SE]) scores of depression and anxiety were reduced in duloxetine more than placebo group, significantly (P = 0.041 and P = 0.049, respectively). The mean (SE) scores of severity of symptom were also reduced in duloxetine more than the placebo group, significantly (P = 0.02). The mean (SE) scores of physical, psychological, and social dimensions of QOL were increased after treatment with duloxetine more than placebo group, significantly (P = 0.001, P = 0.038, and P = 0.015, respectively). The environmental QOL was not increased significantly (P = 0.260).
  
  
  CONCLUSIONS
  Duloxetine is probably effective and safe for reducing depression, anxiety and severity of physical symptoms. It also could increase physical, psychological, and social QOL in patients.
authors.affiliation: Integrative Functional Gastroenterology Research Center, Isfahan University of Medical Sciences, Isfahan, Iran.
authors.forename: Hamed
authors.initials: H
authors.lastname: Daghaghzadeh
authors.affiliation: Department of Psychiatry, School of Medicine, Isfahan University of Medical Sciences, Isfahan, Iran ; Psychosomatic Research Center, Isfahan University of Medical Sciences, Isfahan, Iran.
authors.forename: Fateme
authors.initials: F
authors.lastname: Naji
authors.affiliation: Department of Psychiatry, School of Medicine, Isfahan University of Medical Sciences, Isfahan, Iran ; Psychosomatic Research Center, Isfahan University of Medical Sciences, Isfahan, Iran.
authors.forename: Hamid
authors.initials: H
authors.lastname: Afshar
authors.affiliation: Department of Psychiatry, School of Medicine, Isfahan University of Medical Sciences, Isfahan, Iran ; Psychosomatic Research Center, Isfahan University of Medical Sciences, Isfahan, Iran.
authors.forename: Mohammad Reza
authors.initials: MR
authors.lastname: Sharbafchi
authors.affiliation: Department of Biostatistics and Epidemiology, School of Health, Isfahan University of Medical Sciences, Isfahan, Iran.
authors.forename: Awat
authors.initials: A
authors.lastname: Feizi
authors.affiliation: Department of Psychiatry, School of Medicine, Isfahan University of Medical Sciences, Isfahan, Iran ; Behavioral Science Research Center, Isfahan University of Medical Sciences, Isfahan, Iran.
authors.forename: Mohsen
authors.initials: M
authors.lastname: Maroufi
authors.affiliation: Department of Psychiatry, School of Medicine, Isfahan University of Medical Sciences, Isfahan, Iran ; Psychosomatic Research Center, Isfahan University of Medical Sciences, Isfahan, Iran.
authors.forename: Mahshid
authors.initials: M
authors.lastname: Tabatabaeeyan
authors.affiliation: Integrative Functional Gastroenterology Research Center, Isfahan University of Medical Sciences, Isfahan, Iran.
authors.forename: Peyman
authors.initials: P
authors.lastname: Adibi
authors.affiliation: Integrative Functional Gastroenterology Research Center, Isfahan University of Medical Sciences, Isfahan, Iran.
authors.forename: Hamid
authors.initials: H
authors.lastname: Tavakoli
keywords: Anxiety; depression; duloxetine; inflammatory bowel disease; quality of life; symptom severity